An Open-Label Phase 1 Study to Investigate the Safety and Efficacy of CYP-001 for the Treatment of Adults With Steroid-Resistant Acute Graft Versus Host Disease
Latest Information Update: 24 May 2024
At a glance
- Drugs CYP 001 (Primary)
- Indications Graft-versus-host disease
- Focus Adverse reactions
- Sponsors Cynata Therapeutics
- 22 May 2024 According to a Cynata Therapeutics media release, data from this study has been published in the peer-reviewed journal Nature Medicine.
- 22 May 2024 Results published in a Cynata Therapeutics Media Release.
- 30 Jul 2020 According to a Cynata Therapeutics media release, study close-out procedures are now underway, which will include the preparation of a formal addendum to the clinical study report.